For the year ending 2025-12-31.
| Income Statement | 2025-12-31 | |||
|---|---|---|---|---|
| Research and development | 132,009 | |||
| General and administrative | 38,595 | |||
| Total operating expenses | 170,604 | |||
| Loss from operations | -170,604 | |||
| Interest income, net | 15,953 | |||
| Other income | 0 | |||
| Total other income, net | 15,953 | |||
| Net loss | -154,651 | |||
| Basic EPS | -2.29 | |||
| Diluted EPS | -2.29 | |||
| Basic Average Shares | 67,656,355 | |||
| Diluted Average Shares | 67,656,355 | |||
Mineralys Therapeutics, Inc. (MLYS)
Mineralys Therapeutics, Inc. (MLYS)